1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsMechanisms and Therapeutic Targets for Age-Related Cognitive Decline (R01 Clinical Trial Optional) is sponsored by National Institute on Aging (NIA). This opportunity supports mission-aligned projects and measurable outcomes.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Opportunity Listing - Notice of Intent to Publish a Notice of Funding Opportunity for Early- and Late-Stage Clinical Trials for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive Decline (R01 Clinical Trial Optional) Notice of Intent to Publish a Notice of Funding Opportunity for Early- and Late-Stage Clinical Trials for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive Decline (R01 Clinical Trial Optional) Agency: National Institutes of Health Last Updated: May 13, 2026 View version history on Grants.
gov The National Institute on Aging intends to publish a Notice of Funding Opportunity (NOFO) to 1) invite applications that propose to develop and implement early- to late-stage clinical trials of promising pharmacological and non-pharmacological interventions to prevent and/or treat the cognitive, behavioral,�and neuropsychiatric changes associated with age-related cognitive decline and Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD), and 2) stimulate studies to enhance trial design and methods.
This NOFO will be a reissue of RFA-AG-25-011. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. �The NOFO is expected to be published in December 2024 with expected application due dates in March 2025, June 2025, and October 2025.
This NOFO will utilize the R01 activity code. Details of the planned NOFO are provided below.
Independent school districts Private institutions of higher education Public and state institutions of higher education Federally recognized Native American tribal governments Public and Indian housing authorities For-profit organizations other than small businesses Other Native American tribal organizations Nonprofits non-higher education with 501(c)(3) Grantor contact information NIH OPERA DGSI Systems Policy Branch operasystemspolicy@nih.
gov operasystemspolicy@nih. gov No documents are currently available. Link to additional information Funding opportunity number : Cost sharing or matching requirement : Funding instrument type : Opportunity Category Explanation : Category of Funding Activity : Your account requires additional identity verification.
According to the current listing, eligibility includes: Higher education institutions, Nonprofits, For-profit organizations, Small businesses, Governments, and others. Individuals are encouraged to apply as part of an institutional application. Confirm the full requirements in the official notice before applying.
Mechanisms and Therapeutic Targets for Age-Related Cognitive Decline (R01 Clinical Trial Optional) is funded by National Institute on Aging (NIA). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The National Institute on Aging's FY 2026 AD/ADRD portfolio consolidates the dementia research infrastructure layer — NCRAD, NACC, the new AI and Technology Collaboratory Coordinating Center — into a small number of large, often single-source cooperative agreements. The $113M new-research increment goes elsewhere. For investigators submitting in FY 2026, the structural change matters more than the headline dollar number.
Read articleSeven research teams will run the first clinical trials aimed at extending human healthspan under ARPA-H PROSPR contracts worth up to $144M. The milestone-based contract model breaks every convention of federal biomedical funding.
Read articleARPA-H PROSPR program funds seven research teams up to $144M to develop the first clinical trials targeting biological aging itself, testing rapamycin analogs, semaglutide, and retrotransposon inhibitors.
Read article